Leif W. Ellisen

Jan 6, 2025 | nature.com | Amy H. Comander |Steven J Isakoff |Beverly Moy |Seth A. Wander |Minetta C. Liu |Leif W. Ellisen

AbstractOptimal timing and dosing of adjuvant cyclin-dependent kinase (CDK) 4/6 inhibitor in early breast cancer is controversial. This prospective phase II clinical trial investigated tolerability and safety of two ribociclib dosing schedules.

May 7, 2024 | nature.com | Yumin Wang |Xiaolan Zhu |Aiko Nagayama |SangHoon Lee |Siang-Boon Koh |Bo R. Rueda | +4 more

Correction to: Nature Communications https://doi.org/10.1038/s41467-024-45693-2, published online 21 February 2024In the original version of the published article, the Acknowledgements section was missing a funding source number for Jian Ouyang: National Institutes of Health grant P50 CA274158 (JO). The correct Acknowledgements paragraph is:National Institutes of Health grant R01 GM118833 and CA282939 (LL). National Institutes of Health grant R01 CA181368, CA183976, and 1R21CA237964 (Xi. W).

Mar 20, 2023 | oncologytube.com | Leif W. Ellisen

Antibody-Drug Conjugate Advancements for Breast Cancer Treatment: Updates from SABCS 2022 by Leif Ellisen MDBy Leif Ellisen, MDSo antibody drug conjugates, or as I'll refer to them, ADCs are a really important new class of drugs. They're very complicated structure in that they have three distinct components. One is an antibody that binds to a target on the surface of the tumor cell.

Mar 17, 2023 | oncologytube.com | Leif W. Ellisen

If you can't view this video, your browser does not support HTML5 videos To view this video please enable JavaScript, and consider upgrading to a web browser thatsupports HTML5 video Dr. Leif Ellisen discusses Antibody-Drug Conjugate Advancements for Breast Cancer Treatment: Updates from SABCS 2022 4 days 10 Views Category: Description: Antibody-Drug Conjugate Advancements for Breast Cancer Treatment: Updates from SABCS 2022 by Leif Ellisen MD By Leif Ellisen, MD So antibody drug conjugates,...